Monday
14:30 - 17:00
Hortega Hall

Building the Latest Scientific and Clinical Understanding for the Treatment of Patients with Type 2 Diabetes

Afternoon Session

Steven Kahn (USA), Daniel Drucker (Canada)
Chair Welcome and Opening Remarks
Daniel Drucker (Canada)
Recent Advancements in the Alpha Cell and the Beta Cell: Scientific Spotlight
Hertzel Gerstein (Canada)
Why We Should Still Care about Glycemic Lowering Strategies for Type 2 Diabetes
Juan Frias (USA)
Addressing Clinical Questions - The CompoSIT Trials
Faculty
Clinical Application with Focus on Clinical Inertia- An Interactive Session
Sam Dagogo-Jack (USA)
The Latest Evidence for Ertugliflozin, a SGLT2 Inhibitor for Patients with Type 2 Diabetes
Michael Nauck
Highlighting the Combination of DPP-4 Inhibitors and SGLT2 Inhibitors in the Treatment of Patients with Type 2 Diabetes
Faculty
Clinical Application with Focus on Why and When We Should Take the Next Treatment Steps - An Interactive Session
TBC
Envisioning the Future of SGLT2 Inhibitors in the Treatment of Patients with Diabetes and Renal Disease: Views from the Nephrology Community Speaker
Steven Kahn (USA), Daniel Drucker (Canada)
Final Comments and Summary
Symposia by: